Syngene International Q4 FY26: Revenue Grows 2%, PAT Declines 19% on Consolidated Basis
Syngene International Limited announced its audited financial results for the quarter and year ended March 31, 2026, with consolidated revenue growing 2% to Rs 10,365 million in Q4 FY26. However, profitability declined with consolidated PAT falling 19% to Rs 1,479 million and EBITDA margin contracting 420 basis points to 30.8%. The Board recommended a final dividend of Rs 1.25 per share and announced key management changes including Kiran Mazumdar-Shaw's transition to Executive Chairperson.
*this image is generated using AI for illustrative purposes only.
Syngene International Limited announced its audited financial results for the quarter and year ended March 31, 2026, following a Board meeting held on April 29, 2026. The company reported mixed quarterly performance with revenue growth but declining profitability compared to the previous year. The audited consolidated financial results were published in newspapers on May 1, 2026, under Regulation 33 of SEBI Listing Regulations.
Quarterly Performance Analysis
For the fourth quarter ended March 31, 2026, Syngene International demonstrated contrasting performance metrics. While the company achieved revenue growth, profitability indicators showed a decline compared to the same period last year.
| Q4 Performance Metrics: | Q4 FY26 | Q4 FY25 | Change (%) |
|---|---|---|---|
| Revenue from Operations: | Rs 10,365 million | Rs 10,180 million | +2% |
| Net profit before exceptional items and tax: | Rs 2,020 million | Rs 2,405 million | -16% |
| Net profit before tax: | Rs 1,960 million | Rs 2,405 million | -19% |
| Net profit from ordinary activities after tax: | Rs 1,479 million | Rs 1,833 million | -19% |
| EBITDA: | Rs 3,256 million | Rs 3,625 million | -10% |
| EBITDA Margin: | 30.8% | 35.0% | -420 bps |
Basic earnings per share for Q4 FY26 stood at Rs 3.68 compared to Rs 4.56 in Q4 FY25, while diluted EPS was Rs 3.67 against Rs 4.56 in the previous year.
Annual Financial Performance
The standalone revenue from operations for FY26 reached Rs 34,238 million, while consolidated revenue was Rs 37,387 million compared to Rs 36,424 million in the previous year. Profit for the year stood at Rs 3,049 million on a standalone basis and Rs 3,167 million on a consolidated basis.
| Financial Metric (Rs. in Million): | Standalone FY26 | Standalone FY25 | Consolidated FY26 | Consolidated FY25 |
|---|---|---|---|---|
| Revenue from Operations: | 34,238 | 33,733 | 37,387 | 36,424 |
| Total Income: | 34,907 | 34,438 | 38,094 | 37,142 |
| Total Expenses: | 30,223 | 28,542 | 33,219 | 30,863 |
| Profit for the Year: | 3,049 | 4,680 | 3,167 | 4,962 |
| Total Comprehensive Income: | 734 | 4,599 | 1,207 | 4,815 |
Operating Highlights and Key Management Changes
The company commenced operations at the ADC discovery laboratory during Q4 FY26, establishing end-to-end ADC capabilities from discovery to manufacturing. Quality & Regulatory achievements included completion of 14 audits during the quarter (FY total: 85) and GCP-NABL accreditation. The company was included in the S&P Global Sustainability Yearbook 2026, ranking in the top 10 life sciences companies and top 9% globally.
Key management changes were announced: Kiran Mazumdar-Shaw transitioned from Non-Executive Chairperson to Executive Chairperson effective April 1, 2026, for a five-year term. Siddharth Mittal was appointed Managing Director & Chief Executive Officer effective July 1, 2026, succeeding Peter Bains. Maninder Kapoor Puri was appointed Chief Human Resources Officer and Abhijit Zutshi was appointed Chief Commercial Officer, both effective May 1, 2026.
Dividend Declaration and Board Decisions
The Board of Directors recommended a final dividend of Rs 1.25 per equity share of Rs 10 each for the financial year 2025-26. The record date has been fixed as Friday, June 26, 2026, for determining eligibility for dividend payment. The Board approved the appointment of M/s S. R. Batliboi & Associates LLP as statutory auditors for five years and convening of the 33rd Annual General Meeting on Wednesday, July 29, 2026.
Exceptional Items Impact
The financial results included exceptional items amounting to a net loss of Rs 732 million (standalone) and Rs 766 million (consolidated) for the year. These items primarily relate to the impact of new Labour Codes, including gratuity obligations, and termination benefits extended to employees. The company also wrote off Rs 277 million net as unrecoverable balances in receivables due to foreign exchange rate changes.
Historical Stock Returns for Syngene International
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +8.21% | +7.27% | +12.52% | -29.06% | -25.64% | -18.75% |
What strategic initiatives is Syngene planning to implement to reverse the 36% decline in annual net profit and restore profitability growth?
How might the significant profit margin compression impact Syngene's ability to compete for new contracts in the contract research and manufacturing services sector?
Will the company need to adjust its dividend policy in future quarters given the substantial decline in profitability despite maintaining the Rs 1.25 per share payout?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
